A new treatment represents a "tremendous success" in the face of malaria

US authorities approved a new drug that helps treat a type of malaria with a dose simple.

The new drug targets a type of malaria that appears to be due to "active visualization" parasites, leading to 8.5 million people worldwide each year.

It is difficult to get rid of it because it stays in the liver for many years before re-activity in the patient's body to re-offend the symptoms of the disease from time to time.

Scientists have described the medicine "Tavnokin" as "an extraordinary achievement".

Regulators around the world will study this new drug for the purpose of obtaining authorization for use in their country

"Relapse or relapse of malaria"

Malaria is the most common type outside of sub-Saharan Africa. Children are the most vulnerable to this type of malaria, where they are infected several times with a single sting and are absent from school for long periods and they become more and more numerous whenever they get sick.

The parasite remains in the body throughout the patient's life despite the treatment, so that they serve as a deposit for the disease, because when the parasite regains its activity, mosquitoes can transfer it back to a other person.

This makes the eradication of the disease difficult all over the world.

Now, the US Food and Drug Administration has approved the drug Tavnocene, which helps expel the parasite from its hiding place in the liver and further reduce the incidence of malaria.

This medicine may be given with another medicine to treat immediate inflammation.

A drug that can be used to get rid of the underlying malaria is called primakin, but it must often be administered for 14 days, unlike tavnocine, which receives only one pill.

Many patients stop taking the pill a few days after taking the drug because they feel that their condition has improved, allowing the underlying liver parasites to recover from time to time.

"Caution is Required"

The US Food and Drug Administration says the drug is effective and valid for use in the United States, but noted significant side effects to observe.

The drug is not suitable for people who have an enzyme problem because it causes severe anemia, and there are concerns if they are given a large proportion of psychiatric patients.

Professor Rich Price of Oxford University told the BBC: The parasite in the liver with a dose of Tavnokin is a huge achievement, and in his opinion it represents a significant development. more important in the treatment of malaria in the last 60 years. "